Medical - Diagnostics & Research
Compare Stocks
2 / 10Stock Comparison
INBS vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
INBS vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $3M | $176.36B |
| Revenue (TTM) | $4M | $45.20B |
| Net Income (TTM) | $-11M | $6.86B |
| Gross Margin | 46.2% | 39.4% |
| Operating Margin | -315.3% | 17.8% |
| Forward P/E | — | 19.1x |
| Total Debt | $282K | $40.85B |
| Cash & Equiv. | $1M | $9.86B |
INBS vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Intelligent Bio Sol… (INBS) | 100 | 0.1 | -99.9% |
| Thermo Fisher Scien… (TMO) | 100 | 101.9 | +1.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INBS vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INBS is the clearest fit if your priority is momentum.
- +99.1% vs TMO's +16.8%
TMO carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 8 yrs, beta 1.10, yield 0.4%
- Rev growth 3.9%, EPS growth 7.3%, 3Y rev CAGR -0.3%
- 229.1% 10Y total return vs INBS's -99.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 3.9% revenue growth vs INBS's -1.9% | |
| Quality / Margins | 15.2% margin vs INBS's -315.4% | |
| Stability / Safety | Beta 1.10 vs INBS's 1.91 | |
| Dividends | 0.4% yield; 8-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +99.1% vs TMO's +16.8% | |
| Efficiency (ROA) | 6.4% ROA vs INBS's -64.0%, ROIC 7.5% vs -313.0% |
INBS vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
INBS vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — INBS and TMO each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 12620.2x INBS's $4M. TMO is the more profitable business, keeping 15.2% of every revenue dollar as net income compared to INBS's -3.2%. On growth, INBS holds the edge at +47.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $4M | $45.2B |
| EBITDAEarnings before interest/tax | -$11M | $10.5B |
| Net IncomeAfter-tax profit | -$11M | $6.9B |
| Free Cash FlowCash after capex | -$10M | $6.7B |
| Gross MarginGross profit ÷ Revenue | +46.2% | +39.4% |
| Operating MarginEBIT ÷ Revenue | -3.2% | +17.8% |
| Net MarginNet income ÷ Revenue | -3.2% | +15.2% |
| FCF MarginFCF ÷ Revenue | -2.7% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +47.6% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +43.6% | +11.3% |
Valuation Metrics
INBS leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $3M | $176.4B |
| Enterprise ValueMkt cap + debt − cash | $2M | $207.4B |
| Trailing P/EPrice ÷ TTM EPS | -0.11x | 26.75x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 19.11x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.67x |
| EV / EBITDAEnterprise value multiple | — | 19.04x |
| Price / SalesMarket cap ÷ Revenue | 0.93x | 3.96x |
| Price / BookPrice ÷ Book value/share | 0.43x | 3.34x |
| Price / FCFMarket cap ÷ FCF | — | 28.02x |
Profitability & Efficiency
TMO leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-104 for INBS. INBS carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x. On the Piotroski fundamental quality scale (0–9), TMO scores 6/9 vs INBS's 3/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -103.7% | +13.2% |
| ROA (TTM)Return on assets | -64.0% | +6.4% |
| ROICReturn on invested capital | -3.1% | +7.5% |
| ROCEReturn on capital employed | -189.6% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | 0.10x | 0.76x |
| Net DebtTotal debt minus cash | -$738,104 | $31.0B |
| Cash & Equiv.Liquid assets | $1M | $9.9B |
| Total DebtShort + long-term debt | $281,805 | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | -174.82x | 5.89x |
Total Returns (Dividends Reinvested)
TMO leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TMO five years ago would be worth $10,283 today (with dividends reinvested), compared to $23 for INBS. Over the past 12 months, INBS leads with a +99.1% total return vs TMO's +16.8%. The 3-year compound annual growth rate (CAGR) favors TMO at -4.0% vs INBS's -58.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -71.0% | -19.8% |
| 1-Year ReturnPast 12 months | +99.1% | +16.8% |
| 3-Year ReturnCumulative with dividends | -92.8% | -11.7% |
| 5-Year ReturnCumulative with dividends | -99.8% | +2.8% |
| 10-Year ReturnCumulative with dividends | -99.9% | +229.1% |
| CAGR (3Y)Annualised 3-year return | -58.4% | -4.0% |
Risk & Volatility
TMO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TMO is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than INBS's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TMO currently trades 73.7% from its 52-week high vs INBS's 9.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | 1.10x |
| 52-Week HighHighest price in past year | $24.90 | $643.99 |
| 52-Week LowLowest price in past year | $0.54 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +9.2% | +73.7% |
| RSI (14)Momentum oscillator 0–100 | 36.1 | 43.1 |
| Avg Volume (50D)Average daily shares traded | 86K | 1.9M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
TMO is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $654.67 |
| # AnalystsCovering analysts | — | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 8 |
| Dividend / ShareAnnual DPS | — | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% |
TMO leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). INBS leads in 1 (Valuation Metrics). 1 tied.
INBS vs TMO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is INBS or TMO a better buy right now?
For growth investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger pick with 3. 9% revenue growth year-over-year, versus -1. 9% for Intelligent Bio Solutions Inc. (INBS). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 8x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — INBS or TMO?
Over the past 5 years, Thermo Fisher Scientific Inc.
(TMO) delivered a total return of +2. 8%, compared to -99. 8% for Intelligent Bio Solutions Inc. (INBS). Over 10 years, the gap is even starker: TMO returned +229. 1% versus INBS's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — INBS or TMO?
By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.
(TMO) is the lower-risk stock at 1. 10β versus Intelligent Bio Solutions Inc. 's 1. 91β — meaning INBS is approximately 75% more volatile than TMO relative to the S&P 500. On balance sheet safety, Intelligent Bio Solutions Inc. (INBS) carries a lower debt/equity ratio of 10% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — INBS or TMO?
By revenue growth (latest reported year), Thermo Fisher Scientific Inc.
(TMO) is pulling ahead at 3. 9% versus -1. 9% for Intelligent Bio Solutions Inc. (INBS). On earnings-per-share growth, the picture is similar: Intelligent Bio Solutions Inc. grew EPS 68. 7% year-over-year, compared to 7. 3% for Thermo Fisher Scientific Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — INBS or TMO?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus -346. 2% for Intelligent Bio Solutions Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus -348. 7% for INBS. At the gross margin level — before operating expenses — INBS leads at 40. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — INBS or TMO?
In this comparison, TMO (0.
4% yield) pays a dividend. INBS does not pay a meaningful dividend and should not be held primarily for income.
07Is INBS or TMO better for a retirement portfolio?
For long-horizon retirement investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), +229. 1% 10Y return). Intelligent Bio Solutions Inc. (INBS) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TMO: +229. 1%, INBS: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between INBS and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.